CL2021002075A1 - Anticuerpos anti-trem1 y métodos relacionados. - Google Patents

Anticuerpos anti-trem1 y métodos relacionados.

Info

Publication number
CL2021002075A1
CL2021002075A1 CL2021002075A CL2021002075A CL2021002075A1 CL 2021002075 A1 CL2021002075 A1 CL 2021002075A1 CL 2021002075 A CL2021002075 A CL 2021002075A CL 2021002075 A CL2021002075 A CL 2021002075A CL 2021002075 A1 CL2021002075 A1 CL 2021002075A1
Authority
CL
Chile
Prior art keywords
trem1
related methods
trem1 antibodies
antibodies
methods
Prior art date
Application number
CL2021002075A
Other languages
English (en)
Inventor
Venkataraman Sriram
Aritra Pal
Leonard G Presta
Christopher Chan
Tiep Tu Le
Linda Liang
Original Assignee
Pionyr Immunotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pionyr Immunotherapeutics Inc filed Critical Pionyr Immunotherapeutics Inc
Publication of CL2021002075A1 publication Critical patent/CL2021002075A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En el presente documento se proporcionan anticuerpos anti-TREM1 y métodos relacionados de fabricación y uso de anticuerpos anti-TREM1. También se proporcionan métodos y composiciones para mejorar una respuesta inmune y/o para el tratamiento de una afección relacionada con el sistema inmunitario en un individuo, por ejemplo, cáncer, que comprende destruir, inhabilitar o eliminar células mieloides no estimuladoras usando un anticuerpo anti-TREM1 o un fragmento de unión al antígeno del mismo.
CL2021002075A 2019-02-06 2021-08-05 Anticuerpos anti-trem1 y métodos relacionados. CL2021002075A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962802161P 2019-02-06 2019-02-06
US201962889994P 2019-08-21 2019-08-21

Publications (1)

Publication Number Publication Date
CL2021002075A1 true CL2021002075A1 (es) 2022-04-01

Family

ID=71947128

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002075A CL2021002075A1 (es) 2019-02-06 2021-08-05 Anticuerpos anti-trem1 y métodos relacionados.

Country Status (18)

Country Link
EP (1) EP3921344A4 (es)
JP (1) JP2022523145A (es)
KR (1) KR20210126638A (es)
CN (1) CN113748132A (es)
AU (1) AU2020218525A1 (es)
BR (1) BR112021015479A2 (es)
CA (1) CA3128053A1 (es)
CL (1) CL2021002075A1 (es)
CO (1) CO2021010887A2 (es)
CR (1) CR20210462A (es)
DO (1) DOP2021000165A (es)
IL (1) IL284818A (es)
MX (1) MX2021009500A (es)
PE (1) PE20212269A1 (es)
SG (1) SG11202108570SA (es)
TW (1) TW202037613A (es)
WO (1) WO2020163564A2 (es)
ZA (1) ZA202210284B (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150376294A1 (en) * 2012-12-03 2015-12-31 Rigshospitalet Anti-pad2 antibodies and treatment of autoimmune diseases
EP3295951B1 (en) * 2015-02-19 2020-04-22 Compugen Ltd. Anti-pvrig antibodies and methods of use
WO2017127933A1 (en) * 2016-01-29 2017-08-03 The Governing Council Of The University Of Toronto Frizzled protein-binding agents and methods of use thereof
JP7023853B2 (ja) * 2016-03-04 2022-02-22 アレクトル エルエルシー 抗ｔｒｅｍ１抗体及びその使用方法
CA3020848A1 (en) * 2016-04-15 2017-10-19 Janssen Pharmaceuticals, Inc. Anti-human vista antibodies and use thereof

Also Published As

Publication number Publication date
SG11202108570SA (en) 2021-09-29
CN113748132A (zh) 2021-12-03
CO2021010887A2 (es) 2021-09-09
IL284818A (en) 2021-08-31
JP2022523145A (ja) 2022-04-21
WO2020163564A3 (en) 2020-09-24
WO2020163564A2 (en) 2020-08-13
CR20210462A (es) 2021-12-13
CA3128053A1 (en) 2020-08-13
PE20212269A1 (es) 2021-11-30
MX2021009500A (es) 2021-09-08
KR20210126638A (ko) 2021-10-20
DOP2021000165A (es) 2021-09-30
ZA202210284B (en) 2023-03-29
TW202037613A (zh) 2020-10-16
EP3921344A2 (en) 2021-12-15
BR112021015479A2 (pt) 2021-12-28
EP3921344A4 (en) 2022-10-12
AU2020218525A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
DOP2020000128A (es) Anticuerpos anti-trem2 y métodos relacionados
CO2022013525A2 (es) Anticuerpos contra sars-cov-2 y métodos para usarlos
EA201790755A1 (ru) Модуляция стимулирующих и нестимулирующих миелоидных клеток
PE20190398A1 (es) Anticuerpos nuevos que se unen especificamente a los epitopos del virus del zika y usos de los mismos
ECSP20076683A (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
AR110676A1 (es) Tratamiento del cáncer utilizando receptores de antígenos quiméricos
CL2017000250A1 (es) Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso
EA201792221A1 (ru) Антитела против сортилина и способы их применения
UY36536A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
EA201790339A1 (ru) Комбинированные препараты с антителами к cd40
EP4257199A3 (en) Humanized anti-human-pd-1 antibody
PE20200486A1 (es) Anticuerpos anti-cd33 y metodos para utilizarlos
AR093357A1 (es) Proteinas de union al antigeno y su utilizacion como producto de direccionamiento para el tratamiento del cancer
EA202091810A1 (ru) Антитела к b7-h4 и способы их применения
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
ECSP18084153A (es) Anticuerpos anti-BASIGIN humanizados y uso de los mismos
MX2020010104A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado.
CL2021002075A1 (es) Anticuerpos anti-trem1 y métodos relacionados.
EA202092595A1 (ru) Антитела к siglec-7 и способы их применения
EA202091458A1 (ru) Анти-trem2 антитела и связанные с ними способы
AR118028A1 (es) Anticuerpos anti-trem1 y métodos relacionados
EA202192182A1 (ru) Антитела к trem1 и соответствующие способы
AR115992A2 (es) Proteínas de unión a antígeno que activan el receptor de leptina
EA202090201A2 (ru) Модуляция стимулирующих и нестимулирующих миелоидных клеток
AR118787A1 (es) Moléculas de unión a pd-l1 y uso de las mismas para el tratamiento de enfermedades